Page last updated: 2024-10-15

pcf 39

Description

PCF 39: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	135413509
CHEMBL ID	319760
MeSH ID	M0153686

Synonyms (16)

Synonym
CHEMBL319760
st-789
pcf-39
pcf 39
n2-(5-(hypoxanthin-9-yl)pentyloxycarbonyl)-l-arginine
l-arginine, n2-[[[5-(1,6-dihydro-6-oxo-9h-purin-9-yl)pentyl]oxy]carbonyl]-
104317-64-8
(2s)-5-guanidino-2-[5-(6-oxo-1h-purin-9-yl)pentoxycarbonylamino]pentanoic acid
(2s)-5-(diaminomethylideneamino)-2-[5-(6-oxo-3h-purin-9-yl)pentoxycarbonylamino]pentanoic acid
st 789
l-arginine, n2-(((5-(1,6-dihydro-6-oxo-9h-purin-9-yl)pentyl)oxy)carbonyl)-
n(2)-(5-(hypoxanthin-9-yl)pentyloxycarbonyl)arginine
DTXSID50146386
(s)-5-guanidino-2-((((5-(6-oxo-1h-purin-9(6h)-yl)pentyl)oxy)carbonyl)amino)pentanoic acid
cid 128533
PD161292

Pharmacokinetics

Excerpt	Reference
" A HPLC method validated for pharmacokinetic studies allowed the Authors to assay ST 789 concentration in plasma, urine and tissues."	( Pharmacokinetic investigation of ST 789 in rats and mice. Cardace, G; Mancinelli, A; Martelli, EA; Marzo, A, 1992)

Bioavailability

Excerpt	Reference
"5% of the drug given to be excreted in urine, this leading to conclude that this drug is poorly absorbed through the intestine wall."	( Pharmacokinetic investigation of ST 789 in rats and mice. Cardace, G; Mancinelli, A; Martelli, EA; Marzo, A, 1992)

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID210444	In vitro cytotoxic T-Lymphocyte (CTL) activity relative to interleukin 2 was obtained at a concentration of 10 e -7 M(++ represents 41 - 60% of interleukin 2)	1997	Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18	Synthesis and activity of 6-substituted purine linker amino acid immunostimulants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (15.00)	18.7374
1990's	17 (85.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
caffeine [no description available]	1.97	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	5.38	19	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
benzoin [no description available]	1.98	1	benzoins; secondary alpha-hydroxy ketone	EC 3.1.1.1 (carboxylesterase) inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.38	2	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	1.97	1

Condition	Relationship Strength	Studies
Acute Lymphoid Leukemia [description not available]	1.98	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	1.98	1
Experimental Neoplasms [description not available]	2.38	2
Bacterial Disease [description not available]	1.98	1
Fungal Diseases [description not available]	1.98	1
Bacterial Infections Infections by bacteria, general or unspecified.	1.98	1
Mycoses Diseases caused by FUNGI.	1.98	1
Candida Infection [description not available]	1.97	1
Antibody Deficiency Syndrome [description not available]	1.97	1
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	1.97	1
Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.	1.97	1
Diabetes Mellitus, Adult-Onset [description not available]	1.97	1
Malignant Melanoma [description not available]	1.97	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.97	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	1.97	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.97	1
Adenocarcinoma, Basal Cell [description not available]	1.97	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.97	1

chemdatabank.com